CJC-1295 with DAC Dosage, half-life & reference guide
Also known as CJC-1295 DAC · DAC:GRF
A long-acting growth hormone releasing hormone analogue: the DAC modification extends its half-life to about a week, so one weekly injection keeps GH and IGF-1 raised, lifting baseline GH while natural pulses continue.
- Studied range
- 1–2 mg
- How often
- Weekly
- Half-life
- ~6–8 days
- Evidence
- ●●
●Moderate - Route
- SubQ injection
Studied in research — not a recommendation.
How it works.
GHRH analogue with Drug Affinity Complex that extends half-life to about a week. In human studies one injection raised baseline GH and IGF-1 for days while natural GH pulses continued; recovery, body-composition and sleep effects are extrapolated from GH physiology and user reports. Weekly dosing protocol.
Commonly reported: Water retention and puffiness, sometimes tingling hands, over the first weeks, and tiredness in the days after the shot. Its human data are two small phase 1 studies; it was never approved.
Half-life & active level
The half-life of CJC-1295 with DAC is ~6–8 days (measured in healthy adults: 5.8–8.1 days).
Here's how a typical CJC-1295 with DAC schedule accumulates over four weeks (one-compartment estimate).
An estimate from the half-life above, not a measurement. See your own curve build live in the half-life calculator.
Where CJC-1295 with DAC works.
Appetite & metabolism
Reported by users. Commonly reported in this window: measurable fat loss and lean gains.
Muscle
Reported by users. Commonly reported: faster recovery, fuller-looking skin and a shift in body composition, with water retention usually settled by now.
Energy & longevity
In people. In human studies one injection raised baseline GH and IGF-1 for days while natural GH pulses continued.
An area lights for what a peptide is used for and what people report, with the evidence beside it. It isn’t a promise that it works there.
Week by week.
What to expect in the first 8 weeks
- Onset
- 1–3 weeks
- Peak effect
- 8–12 weeks
- Duration
- 8–12 weeks
Day 1–14Clinical
GH is building; water retention is common
The DAC modification means one injection keeps GH raised for about a week. Commonly reported: water retention in the first couple of weeks (don't mistake it for fat gain) and deeper sleep.
The science
CJC-1295 DAC binds to serum albumin via the Drug Affinity Complex, giving a half-life of about 6–8 days. In phase 1 trials one injection raised IGF-1 1.5- to 3-fold for 9–11 days (Teichman 2006). The water retention is GH-mediated sodium retention in the kidneys, a common and usually transient effect.
Sources- Teichman et al. (2006)
Updated Sep 2026
Day 14–42Community
Recovery and skin quality are changing
Weeks 2 to 6 are where the DAC variant's weekly convenience shows. Commonly reported: faster recovery, fuller-looking skin and a shift in body composition, with water retention usually settled by now.
The science
CJC-1295 DAC raised baseline (trough) GH about 7.5-fold while the frequency and size of natural GH pulses stayed the same (Ionescu 2006); that raised baseline drives the sustained IGF-1 rise. Body-composition effects haven't been measured in trials.
Sources- Teichman et al. (2006)
- Ionescu & Frohman (2006)
Updated Sep 2026
Day 42–84Clinical
Peak recomp — watch for carpal tunnel
Commonly reported in this window: measurable fat loss and lean gains. Watch for carpal tunnel symptoms (tingling or numbness in the hands), which come from GH-driven fluid retention around nerves, and raise them with your clinician if they appear.
The science
Fluid retention (swelling, joint pain, carpal tunnel) is the most common GH-related effect and eases with dose reduction or stopping. Glucose effects matter too, and FDA says it has identified serious adverse events with CJC-1295, including increased heart rate and systemic vasodilatory reactions. IGF-1 monitoring is advisable at 8+ weeks to ensure levels remain within a safe range.
Sources- Teichman et al. (2006)
Updated Sep 2026
Any dayClinical
What CJC-1295 DAC is built on
CJC-1295 has phase 1 data showing sustained GH and IGF-1 elevation; its phase 2 trial was stopped in 2006. Developed by ConjuChem, the DAC version is well characterized pharmacologically, and the weekly convenience is real. The community generally prefers the no-DAC variant for more pulse-like dosing.
The science
Teichman et al. (2006), two phase 1 trials in healthy adults: single ascending doses raised mean GH 2- to 10-fold for 6 days or more, and IGF-1 rose 1.5- to 3-fold for 9–11 days (up to 28 days with repeat doses). GH pulses stayed intact while baseline GH rose (Ionescu 2006). The phase 2 in HIV-associated abdominal fat was stopped in 2006 after a participant death judged unrelated, so no patient trial was completed.
Sources- Teichman et al. (2006)
- Ionescu & Frohman (2006)
Updated Sep 2026
Day 1 is the day you start it.
Phase 1 trial data showing sustained GH/IGF-1 elevation (Teichman 2006). Body composition outcomes mainly community-reported.
Moderate evidence
Mixing and a typical run.
Example numbers
Reconstitution example
Reconstitute a 10 mg vial of CJC-1295 with DAC with 2 mL of bacteriostatic water and a 2 mg dose is 40 units on a U-100 syringe, about 5 doses per vial.
- Vial
- 10 mg
- Water
- 2 mL
- Amount
- 2 mg
Draw to40 units
0.5 mL insulin syringe · 50 units
Run notes
- Cycle
- 8–12 weeks common. Weekly dosing means effects accumulate — give adequate time off between cycles.Community practice — opinions vary. Not a clinical recommendation.
- Timing
- Once weekly SubQ. Day and time flexible — consistency matters more than specific timing.
- Route
- SubQ injection
- Stacks
- Ipamorelin, BPC-157
Safety.
Common side effects
- Water retention
- Headache
- Flushing
- Injection site pain
- Fatigue
- Carpal tunnel symptoms
Goes with.
Compared with.
Questions people ask.
What is CJC-1295 with DAC?
A long-acting growth hormone releasing hormone analogue: the DAC modification extends its half-life to about a week, so one weekly injection keeps GH and IGF-1 raised, lifting baseline GH while natural pulses continue.
How is CJC-1295 with DAC dosed in research?
The research range for CJC-1295 with DAC is 1–2 mg, weekly. Studied in research — not a recommendation.
How long does CJC-1295 with DAC last?
The half-life of CJC-1295 with DAC is ~6–8 days (measured in healthy adults: 5.8–8.1 days).
What do people report on CJC-1295 with DAC?
Commonly reported on CJC-1295 with DAC: water retention and puffiness, sometimes tingling hands, over the first weeks, and tiredness in the days after the shot. Its human data are two small phase 1 studies; it was never approved.
Is CJC-1295 with DAC safe?
The research basis for CJC-1295 with DAC is moderate: animal studies + some human data. Common side effects in the library: water retention, headache, flushing, injection site pain, fatigue and carpal tunnel symptoms.
What does CJC-1295 with DAC stack with?
Common stacks for CJC-1295 with DAC: Ipamorelin and BPC-157.
Reference.
- Cadence
Weekly
- Half-life
~6–8 days
~6–8 days (measured in healthy adults: 5.8–8.1 days)
- Research basis
●●
●ModerateAnimal studies + some human data
PepVault for iPhone
Track CJC-1295 with DAC in PepVault
Log every dose, keep your vial and the doses left in it and watch its estimated active level. 7 days free on the yearly plan for new subscribers.
Open the calculatorHow the vial count worksExplore the live demo
Reviewed How we check the library